Year: 2013
Type: article
Abstract: As specialists in applying the procedure of allogeneic immunotherapy for the treatment of various diseases, we often struggle with “getting our timing right.” As noted by Joshua Harris, “The right thing at the wrong time is the wrong thing.” Thus, in this issue of Biology of Blood and Marrow Transplantation, Warlick et al. [1] highlight a topic of great interest. In what setting are patients who enter nonmyeloablative allogeneic transplant “optimized” for long-term outcome? Do we consider the potential logarithmic cell kill provided by pretransplant consolidation, with potential to minimize residual disease, as outweighing the risk of additional damage done to the adult body exposed to repeated cycles of chemotherapy, especially regarding hepatic, nutritional, and infectious concerns in recovery from transplantation?
Author: David Rizzieri
Institution: Duke Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2097947500